Multiple Keratoacanthomas, Philadelphia Chromosome+ Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report by Thukral, Siddhant et al.
The International Journal of Medical Students Int J Med Students   •   2015  |  Sep-Dec  |  Vol  3  |  Issue 3155
IJMS
International Journal of 
Medical Students Case Report
Multiple Keratoacanthomas, Philadelphia Chromosome+ 
Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report
Siddhant Thukral,1 Lloyd E. King Jr.,2 David H. Horowitz.2
Abstract
Background: Treatment for adult Philadelphia chromosome+ acute lymphoblastic leukemia includes using dasatinib, a tyrosine kinase inhibitor. Cutaneous 
squamous cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors of tyrosine kinases.  No documentation of 
dasatinib inducing multiple keratoacanthomas, squamous cell carcinomas type during treatment of Philadelphia chromosome+ acute lymphoblastic leukemia 
is currently available. Case: A 77-year-old Caucasian male presented to the dermatology clinic two months after starting treatment with dasatinib for Philadel-
phia chromosome positive+ acute lymphoblastic leukemia. Biopsies confirmed the lesions on the arms, chest, legs and back as keratoacanthoma (KA) type of 
squamous cell carcinomas (SCCs). The cutaneous lesions were surgically removed and no new or recurrent lesions were detected since their initial rapid onset 
despite continued dasatinib therapy. Conclusion: This report of the rapid onset of keratoacanthoma type squamous cell carcinomas in a patient with Phila-
delphia chromosome+ acute lymphoblastic leukemia treated with dasatinib is presumed to be the first due to the rarity of adult Philadelphia chromosome+ 
acute lymphoblastic leukemia. This report documents another tyrosine kinase inhibitor that is associated with the eruption of keratoacanthomas, and adds 
to the literature regarding the regularity of this relatively common side effect, which may have treatment other than surgery if only a few lesions are present.
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Introduction
Acute lymphoblastic leukemia (ALL) is a malignant disorder of 
lymphoid progenitor cells with unknown pathogenicity diag-
nosed in between 3,000 to 4,000 people in the U.S each year, 
two-thirds of them are children.1-2 In adult ALL, the most fre-
quent chromosomal translocation is t(9;22), known as the Phi-
ladelphia chromosome, which binds breakpoint cluster (BCR) 
signalling proteins to ABL tyrosine kinases (TKs) resulting in 
uncontrollable ABL tyrosine kinase (TK) activity.1-3 
In the past two decades, tyrosine kinase inhibitors (TKIs) 
that specifically inhibit certain TKs, such as those involved in 
ALL’s pathogenesis, have successfully treated ALL.4-5 Dasatinib, 
an orally available second-generation ABL kinase inhibitor, is 
approved to treat adults with Philadelphia chromosome posi-
tive (Ph+) ALL who developed resistance to or intolerance of 
other ABL TKIs such as imatinib (Gleevec®).3-6 
Multiple factors such as exposure to ionizing radiation, che-
mical agents, UV radiation, human papilloma virus, and im-
munosuppression can predispose patients to develop diffe-
rent types of cutaneous squamous cell carcinomas (SCCs).5-7 
Keratoacanthomas (KAs) are currently classified as one type 
of cutaneous squamous cell carcinoma (SCC), but this con-
cept is controversial as another opinion is that it is a distinct 
self-resolving squamoproliferative lesion that may regress due 
to upregulation of the cell death/apoptosis pathway.8 Clinically, 
KAs may be a single or multiple rapidly developing crateriform 
lesions in a few weeks or months and may spontaneously re-
solve in 6 months without any treatment (Figure 1). Biopsies 
of KAs may or may not have different diagnostic features from 
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          Key Points:
• Multiple keratoacanthoma type squamous cell carcinomas have not 
previously been documented in patients with Philadelphia chromosome 
positive acute lymphoblastic leukemia treated with dasatinib. 
• Keratoacanthomas are initially rapid growing neoplasms (10 days - 2 
months) that stabilize and often regress without surgical removal unli-
ke other types of cutaneous squamous cell carcinomas.
• Treating adult Philadelphia chromosome+ acute lymphoblastic leuke-
mia with dasatinib and other tyrosine kinase inhibitors may cause rapid 
onset of keratoacanthoma type squamous cell carcinomas.
other types of cutaneous SCCs such as those arising from the 
much more common actinic keratosis and in situ squamous 
cell carcinomas. A clinical history of rapid onset of such le-
sions within a few months is a valuable clue to their diagnosis 
and establishing their prognosis. Herein we report a case of 
a patient who developed multiple KAs within two months af-
ter starting treatment with dasatinib for Ph+ ALL. Sometimes 
KAs arise due to hyperactive epidermal growth factor receptor 
tyrosine kinases that subsequently activate the RAS and MAPK 
signalling pathways.5-9 However, the incidence and treatment of 
KA type SCCs induced by TKIs are not well defined, but investi-
gations to clarify if KAs are SCCs and distinct from a molecular 
perspective are on-going.6-8 A signed copy of consent to publish 
this manuscript was obtained from the patient.
The Case
A 77-year-old Caucasian male presented to the dermatology 
clinic for sudden onset of nodular skin lesions found on the 
arms, legs, back, and chest. The patient showed no significant 
evidence of severe sun exposure or any ionizing radiation that 
would predispose him to develop these lesions. He had a me-
dical history of a malignant melanoma on the left side of his 
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upper back treated 9 years prior to his dermatology clinic visit. 
He had no family history of ALL, but his mother had treatment 
for a basal cell carcinoma. The diagnosis of Ph+ ALL was con-
firmed two months prior to his initial dermatology clinic visit 
and his skin lesions were first noticed weeks after starting 
treatment for Ph+ ALL. His oncologist started treatment with 
oral 400 mg tablet of antiviral drug Acyclovir taken twice dai-
ly, oral multi BCR/ABL TKI dasatinib (Sprycel®) 140 mg tablet 
taken once daily, and oral ondansetron (Zofran®) 8 mg tablet 
to be taken as needed. Within two months after starting this 
treatment, the patient achieved molecular remission of Ph+ 
ALL with undetectable BCR-ABL. The patient maintained the 
treatment regimen throughout his oncology clinic visits. While 
on this treatment regimen that included dasatinib, the patient 
developed mild anemia (RBC 3.50 M/uL). However, the patient 
did not have any fevers, chills, night sweats, nausea, vomiting, 
abdominal pain, chest pain, shortness of breath, or skin rash. 
The patient’s oncologist confirmed his adherence to medication 
with regularly scheduled visits. The patient’s wife also confir-
med compliance with treatment regimen, and the patient was 
overall happy with the treatment results. 
The patient’s skin lesions were nodular, erythematous, hyper-
keratotic, and first observed two weeks after starting treat-
ment with dasatinib (Figure 1). The initial shave biopsy in the 
dermatology clinic was a 13 x 13 x 6mm tan nodule on the 
left volar forearm (Figure 1) to identify if it was a KA type 
of SCC, dermatitis medicamentosa, leukemia cutis, basal cell 
carcinoma or, less likely, a recurrent malignant melanoma. The 
dermatopathologist confirmed this nodule was a KA variant of 
SCC with clear margins (Figure 2). On the patient’s next derma-
tology clinic visit one week following the initial skin biopsy, a 
repeat skin biopsy on the left superior forearm confirmed the 
second lesion was also a KA variant of SCC. These two KAs with 
typical biopsy features and clinical multiple other KAs (23 in 
total), their rapid clinical onset, and previous reports of KAs in 
patients treated with other TKIs (sorafenib, nilotinib) are con-
sistent with the patient developing KAs induced by dasatinib 
used to treat Ph+ ALL.
On follow-up visit three weeks after the preceding biopsy, no 
new lesions were detected and existing lesions showed hyper-
keratotic regression typical of KAs. Due to a risk of slow healing 
and excessive bleeding, a referral to a Mohs surgeon was made 
to excise the 20 remaining KAs below the patient’s waist. The 
three remaining KAs above the waist were excised in the der-
matology clinic with sufficient time between visits to prevent 
slow healing and/or bleeding complications. The oncologist re-
commended that the patient continue 140 mg dasatinib and 
stop taking Acyclovir. An initial management challenge was to 
determine which physician should be managing his skin le-
sions – his oncologist, the dermatologist, or the Mohs surgeon? 
After initially cancelling his dermatology clinic appointment, 
convenient appointment times were made for the patient to 
see the oncologist and the dermatologist. Both clinicians and 
the patient are satisfied with the outcome of treatment and 
he continues close monitoring to detect new lesions or other 
adverse events. The patient was eager to achieve resolution 
of his skin lesions so he was compliant with all treatments, 
diagnostic tests, and has continued dasatinib for treatment of 
his Ph+ ALL.
Discussion
Keratoacanthomas (KAs) are commonly thought to be a low-gra-
de skin cancer or a distinct self-resolving squamoproliferative 
lesion that is very similar phenotypically to squamous cell car-
cinoma (SCC) and originates in the skin's pilosebaceous glands 
or hair follicles.10 KAs typically and rapidly grow a few weeks to 
a few months, as a crateriform lesion with hyperkeratotic re-
gression.10 The patient’s rapidly growing lesions were scattered 
throughout his chest, back, and extremities with no correlation 
between their location and intense sun exposure sites starting 
two months after treatment for Ph+ acute lymphoblastic leu-
kemia (ALL) by his oncologist who referred the patient to the 
dermatology clinic. A shave biopsy was determined to be the 
ideal diagnostic approach. While multiple shave biopsies are 
diagnostically useful, only one or two biopsies were performed 
per visit to insure that the patient would not bleed excessively. 
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Figure 1. Squamous Cell Carcinoma, Keratoacanthoma Type on the 
patient’s left volar forearm.
Figure 2. Biopsy specimen confirmation of Squamous Cell Carci-
noma, Keratoacanthoma type from Patient’s Left Volar Forearm.
Legend: SCC, KA types are characterized “by an incomplete or asymmetric 
crateriform pattern with bulging borders and irregular nests of squamous 
cells invading the dermis”. 10 Hematoxylin and Eosin (H&E) stain used on 
biopsy specimen at 10x magnification.
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The Mohs technique was determined to be the most appropria-
te for lesions below the patient’s waist due to its accuracy and 
minimally invasive approach. 
To define the etiology of the sudden and aggressive appearing 
KAs, the focus changed to a family history of skin cancers, a 
comorbid neoplasm related to Ph+ ALL, or possible adverse re-
action to one of his medications including the tyrosine kinase 
inhibitor, dasatinib, which has an extensive list of cutaneous 
side effects including rashes, redness, peeling, but currently 
there is no reference of cutaneous SCC, KA type (Sprycel. Avai-
lable from: http://www.sprycel.com/side-effects, updated 2015 
August 15; cited 2015 August 16).  
The current TKI literature implies a relationship between erup-
tive epitheliomas such as KAs and the TKIs  sorafenib and nilo-
tinib.5,10-11 There are multiple mutations associated with Ph+ ALL 
and interest is focused on the signaling pathways are targeted 
in the pathogenesis of KA type of SCC by dasatinib and other 
TKIs.12 One study documented a patient developing multiple 
cutaneous SCCs (KAs) shortly after starting treatment with ni-
lotinib for chronic myeloid leukemia (CML).5 Multiple patients 
treated for solid tumors with sorafenib also developed multiple 
KA type lesions within few weeks to months after starting treat-
ment.10-11 Our in-depth literature review did not find any docu-
mented cases of a Ph+ ALL with a patient with KA type eruptive 
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epitheliomas or SCCs after starting therapies using dasatinib. 
Treatment options for patients treated with TKIs included a CML 
patient who developed KA type SCC lesions after starting treat-
ment with nilotinib and the number of new lesions decreased 
after retinoid treatment and all existing SCCs were surgically 
excised.5 The induction of KAs may be TKI specific as patients 
with KAs treated with sorafenib for solid tumors had regression 
of existing KA, SCC type after switching to a different TKI (suni-
tinib) or discontinuing sorafenib.10-11
The mechanisms involved in causing the SCC, KA type lesions 
in our patient are not yet documented. Since no prior report 
was found to document eruptive epitheliomas, KAs, or SCC 
types were induced by dasatinib in the treatment of Ph+ ALL, 
we presume that this case is the first of its kind.
Conclusion
The treatment of Ph+ ALL with dasatinib has been associated 
with numerous different systemic and skin adverse events; 
however, its association with the rapid onset of keratoacantho-
ma type, squamous cell carcinomas in this rare form of ALL is 
not previously documented. With increased usage of dasatinib 
to treat adult Ph+ ALL, it is important to recognize its associa-
tion with the possible rapid development of eruptive epithelio-
mas, keratoacanthoma type.
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